MAP2K7 and uveitis: Association with ocular inflammation has been documented, albeit with a limited sample size, in the phase III coBRIM study (4/5 patients with a history of ocular inflammation developed symptomatic retinopathy among 247 patients treated with cobimetinib + vemurafenib).31 For this patient, MEK inhibitor therapy was initiated again after 6 months, and although serous retinal detachment was detected again, no inflammatory process or uveitis emerged.35 With severe ocular symptoms, it is reasonable to trial cessation of the medicine to observe if there is a swift resolution of the symptoms.